Amendment No. 4 to License Agreement Between Stanford University and NeoRx Corporation

Summary

Stanford University and NeoRx Corporation have amended their existing license agreement, effective July 11, 1997. This amendment changes the terms regarding sublicensing: generally, sublicensees cannot further sublicense, except for NeoRx's proposed sublicensee, Janssen Pharmaceutica, which may further sublicense with notification to Stanford. Any sub-sublicensee, however, is not allowed to further sublicense. The amendment is executed by authorized representatives of both parties.

EX-10.10 4 v70750ex10-10.txt EXHIBIT 10.10 1 Exhibit 10.10 AMENDMENT NO. 4 to the License Agreement Effective June 1, 1987 Between STANFORD UNIVERSITY and NEORX CORPORATION Effective as of July 11, 1997, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERITY, a body having corporate powers under the laws of the State of California ("STANFORD") and NEORX CORPORATION, a Washington Corporation, having a principal place of business at 410 W. Harrison, Seattle, Washington 98119 ("NEORX"), agree as follows: AMENDMENT 2.3 - Paragraph 12.3(a) of the License is hereby amended to read in its entirety, as follows: 12.3 (a) - Sublicense terms and conditions shall reflect that any sublicensee shall not further sublicense; provided, however, that NEORX's proposed sublicensee, JANSSEN PHARMACEUTICA, may further sublicense provided that notification is sent to STANFORD upon signing of the sublicense and that any sub-sublicensee may not further sublicense; and IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 4 in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES NEORX CORPORATION OF THE LELAND STANFORD JUNIOR UNIVERSITY By /s/ [SIGNATURE ILLEGIBLE] By /s/ PAUL G. ABRAMS -------------------------------- --------------------------- Title Director Technology Licensing Title President & CEO -------------------------------- --------------------------- Date July 15, 1997 Date 7/11/97 -------------------------------- ---------------------------